BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh
BioTime announced that the company has obtained a worldwide license to intellectual property (IP) assets from University of Pittsburgh. The technology was developed in part in collaboration with BioTime scientists and includes composition and methodologies to develop 3-D retinal tissue constructs from pluripotent stem cells for their implantation in patients with advanced stages of retinal degeneration.
“This significant addition to our expanding portfolio is a major step toward our goal of becoming an industry leader in regenerative opthalmology innovation,” Adi Mohanty, Co-Chief Executive Officer of BioTime, said in a company news release. “These assets enable us to develop treatments for advanced forms of blindness for which there are currently no treatments available. We intend to build a strong franchise for serious forms of eye disease.”
“We anticipate that this technology, codeveloped with the University of Pittsburgh, for retinal repair will allow us to generate 3-dimensional laminated human retinal tissue in a controlled manufacturing process. This could lead to vision restoration treatments for a variety of blinding retinal degenerative diseases, particularly retinitis pigmentosa, macular degeneration, and diabetic retinopathy, among other diseases and conditions,” Michael D. West, PhD, Co-Chief Executive Officer of BioTime, said in the news release.
Key aspects of the technology are described in three presentations at the annual meeting of the Society for Neuroscience, November 12-16, 2016 in San Diego by Dr. Igor Nasonkin, lab head at BioTime, and one upcoming presentation at the ISSCR congress in Basel Switzerland February 27-March 1.
You must be logged in to leave a comment.